#### **ORIGINAL ARTICLE**



# AA genotype of *PLIN1* 13041A>G as an unfavourable predictive factor of malnutrition associated with fat mass loss in locally advanced head and neck cancer male patients treated with radiotherapy

Tomasz Powrózek<sup>1</sup> · Anna Brzozowska<sup>2</sup> · Marcin Mazurek<sup>1</sup> · Monika Prendecka<sup>1</sup> · Iwona Homa-Mlak<sup>1</sup> · Radosław Mlak<sup>1</sup> · Teresa Małecka-Massalska<sup>1</sup>

Received: 9 December 2019 / Accepted: 6 August 2020 / Published online: 15 August 2020  $\odot$  The Author(s) 2020

#### Abstract

**Introduction** Malnutrition is a frequently diagnosed condition in head and neck cancer (HNC) patients after radiation therapy (RTH). Malnutrition causes adipose tissue dysfunction associated with intensified lipolysis and disruption of the activity of mechanisms that protect adipose tissue against this process, which include the protective function of perilipin.

**Material and methods** The purpose of this study was the evaluation of the predictive value of 13041A>G *PLIN1* polymorphism in the development of malnutrition related to adipose tissue loss in a group of 80 patients with locally advanced HNC treated by means of radical radiation therapy.

**Results** After the completion of RTH, men with AA genotype had significantly lower fat mass (FM compared to men with G haplotype; FM:  $13.84 \pm 6.36$  kg and  $19.06 \pm 6.30$  kg (p = 0.009). In consequence of RTH, the AA genotype carriers lost an average of 37.01% adipose tissue mass and patients with GA and GG genotypes lost 12.82 and 0.31% (p = 0.035), respectively. AA genotype was also associated with higher chance of  $\ge 10\%$ ,  $\ge 20\%$  and  $\ge 30\%$  FM loss in the course of RTH (OR = 13.78; 5.78; 2.28).

**Conclusions** The evaluation of such molecular factors as SNP 13041A>G may have higher predictive value in the development of malnutrition associated with severe loss of fat mass than the subjective scales, e.g., SGA and NRS-2002. The presence of AA genotype on men with HNC before RTH may facilitate earlier nutritional intervention and supportive treatment aimed at limiting or preventing body mass and fat mass loss during the applied treatment.

Keywords Head and neck cancer · Malnutrition · Radiotherapy · PLIN1 · Fat mass loss

# Introduction

According to the European Society for Clinical Nutrition and Metabolism (ESPEN), malnutrition is a state resulting from lack of intake or uptake of nutrition that leads to altered body

**Electronic supplementary material** The online version of this article (https://doi.org/10.1007/s00520-020-05675-8) contains supplementary material, which is available to authorized users.

Tomasz Powrózek tomaszpowrozek@gmail.com composition and body cell mass leading to diminished physical and mental function and impaired clinical outcome from disease [1]. It is estimated that this condition may concern 3–52% head and neck cancer (HNC) patients at the time of disease diagnosis. This is related to the anatomical location of the tumour at the border of the respiratory and digestive systems, its stage and the degree of the host metabolism disturbance leading to the acquisition of nutrients necessary for further development and expansion of the cancer process [2]. Standard therapeutic options for HNC include surgery, chemotherapy and radiotherapy (RTH) or a combination of these methods. RTH or radiochemotherapy (RCTH) are characterized by high aggressiveness in the destruction of tumour tissue. Unfortunately, they also damage healthy tissues, which results in either the development of malnutrition or intensification of the already existing

<sup>&</sup>lt;sup>1</sup> Department of Human Physiology, Medical University of Lublin, Lublin, Poland

<sup>&</sup>lt;sup>2</sup> St. John of Dukla Lublin Region Cancer Center, Lublin, Poland

malnutrition leading to cachexia [3, 4]. The negative influence of the therapy on the nutritional status of HNC patients is confirmed by a high incidence of malnutrition (44–88%) observed after the treatment completion in this group of patients and the toxicity of the therapy leading to digestive disorders such as vomiting, diarrhoea, xerostomia, oral mucositis, taste disorder and loss of appetite [2, 5, 6]. These side effects of the treatment lead to a significant reduction in the supply of food and energy. This promotes the intensification of catabolic processes within the organism, which results in gradual loss of body mass and its remodelling (changes in body composition) associated with progressive proteolysis and/or lipolysis of muscle and/or fat tissue [7–9].

Fat tissue provides the main and dynamic storage of energy substances in the body-in case of their surplus they are stored in fat tissue, but in case of their deficiency they are released from it and consumed depending on the systemic needs. It is also an important metabolic and endocrine centre of the body. In the course of malnutrition and cancer cachexia, the adipose tissue dysfunction is observed, associated with limited anabolism and increased cellular catabolism as a result of the action of substances released by the tumour and host organism. In the course of malnutrition and cachexia, the processes of both lipogenesis and conversion of white fat into brown fat, accompanied by its further lipolysis, are observed [10–12]. In the course of metabolic disorders resulting from the neoplastic process, there is also a disturbance of protective mechanisms preventing lipolysis, which include the activity of perilipin. Perilipin is encoded by PLIN1 gene and located in adipocytes of white and brown adipose tissue. Its main task in the state of energy balance of the body is to protect fat drops with triglycerides (TG) stored inside them from the access of HSL and ATGL lipases, and thus regulating the process of fat storage and decomposition. This function can be modulated depending on the energy needs, i.e. in states of satiation and energy surplus, the lipase access to TG is inhibited; while in states of starvation and catabolism, perilipin supports TG breakdown by lipases [13–15]. This underlines the potential contribution of perilipin to fat metabolism in conditions such as malnutrition and cachexia, accompanied by strong catabolism. The function of perilipin can be regulated by single nucleotide polymorphisms (SNPs) present in the gene that encodes it. To date, several studies have confirmed the association of PLIN1 SNPs with the risk of obesity, insulin resistance, diabetes mellitus, higher body weight and hypertension [16]. Among SNPs, rs2304795 (13041A>G) located in the 3' region of the PLIN1 gene seems to have a significant role in the regulation of perilipin function and adipose tissue turnover in the body, as its close association with BMI, body weight and obesity risk has been reported [17].

So far, there have been no data available in the literature regarding the influence of *PLIN1* polymorphisms on the risk of the development of malnutrition and cachexia in malignant tumours, including HNC. Since HNC patients belong to a

group with a high risk of malnutrition and metabolic disorders associated with fat tissue function, the evaluation of *PLIN1* gene status seems to have a potential predictive value for the development of malnutrition accompanied by a significant loss of fat mass (FM). The purpose of this study was the evaluation of the influence of 13041A>G *PLIN1* polymorphism on the risk of the development of malnutrition related to adipose tissue loss in the course of treatment of patients with locally advanced HNC by means of radical RTH.

### Materials and methods

## Study group

Eighty patients (60 men and 20 women) with locally advanced squamous-cell HNC were included in this study. Among the HNC subtypes, laryngeal tumours (55% of the study group) and stage IV tumours (76.2% of the study group) were predominant. The patients were diagnosed and treated in the Department of Oncology of the Medical University of Lublin between 2015 and 2019. Patients with the history of surgical treatment accounted for 60% of the study group. The study group characteristics and the parameter values assessed before RTH are presented in Table 1. In order to qualify patients for the study protocol, we applied the appropriate inclusion and exclusion criteria. The following inclusion criteria were used: (1) age > 18 years; (2) performance status  $\leq 1$  according to ECOG-WHO scale; (3) confirmed diagnosis of HNC in stages III-IV; (4) patients who completed full course of RTH; (5) patients whose health status enabled them to grant their written informed consent to participate in the study. The following exclusion criteria were used: (1) patients with pacemakers or cardioverter-defibrillators; (2) patients with amputated limbs or with prostheses or metal implants; (3) the presence of chronic kidney, heart or liver diseases; (4) abnormal plasma sodium and potassium concentrations.

The studies were approved by the Bioethical Committee of the Medical University in Lublin (no of consent: KE-0254/ 232/2014). Written informed consent to participate in the study was obtained from each patient.

### Radiotherapy

All patients qualified for the study were treated with radical RTH (7 cycles of treatment) using ONCOR linear accelerator (Siemens). The Intensity Modulated Radiation Therapy (IMRT) technique was used to administer a total dose of 66–70 Gy (daily dose 2 Gy) in 35 fractions. Patients who previously underwent surgical treatment received 66 Gy in 33 fractions for high risk volume, the intermediate and low risk subclinical volumes received 60 Gy and 54 Gy, respectively. Patients undergoing concomitant chemotherapy received from 1 to 4 courses of cisplatin and 5-fluorouracil (PF).

#### Table 1 Baseline characteristics of the study group

$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Factor		Study group $(n = 80)$
FendleFendle20 (25%)456-342 (32.5%)-6338 (47.5%)38 (47.5%)Histopthological diagnosisSquanous cell carcinoma80 (100%)Tamour location12 (14.9%)12 (14.9%)Tange0ropharyax4 (55.3%)Tage323 (23.8%)Nange012 (14.9%)Nange013 (13.9%)Nange013 (13.9%)Participation13 (13.9%)13.9%)Participation14 (13.9%)13.9%)Participation14 (13.9%)13.9%)Participation14.1%)13.9%)Participation14.1%)13.9%)Participation14.1%)13.9%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation14.1%)14.1%)Participation <th>Gender</th> <th>Male</th> <th>60 (75%)</th>	Gender	Male	60 (75%)
Age, mean (range)563619 (42-87)<		Female	20 (25%)
≥63     34 (37.5%)       Histogathological diagnosis     Squamous cell carcinoma     80 (100%)       Tamour location     42 (55.5%)       Tumour location     42 (55.5%)       Tanour location     36 (45%)       Tage     20 (28.8%)       1 stage     41 (45.6%)       N stage     0     42 (52.5%)       N stage     1     11 (13.8%)       1 stage     1     11 (13.8%)       2 stage     1     11 (13.8%)       3 stage     1     16 (23.5%)       1 stage     1     16 (23.5%)       1 stage     1     16 (23.5%)       1 stage     1     16 (3.3%)       1 stage     1     16	Age, mean (range)		63±9 (42–87)
<63<8(47.5%)Histopathological diagnosisSquamous cell carcinoma80 (10%)Tamou locationLaynx44 (55%)Opopharynx32 (44%)32 (44%)T stage12 (149%)32 (45%)1 stage12 (149%)32 (45%)N stage645 (56.3%)N stage11 (13.5%)18 (22.5%)111 (13.5%)18 (22.5%)111 (13.5%)18 (22.5%)113 (56.3%)78.7%)Disease stage11 (14.3%)78.7%)Performance status (PS)060.5%)Performance status (PS)061 (76.3%)Prior surgical treatmentYes32 (40%)Type of treatmentYes32 (40%)Prior surgical treatmentYes30 (43.7%)No50 (62.5%)30 (35.%)No50 (62.5%)30 (35.%)No-moker78 (83.%)30 (43.7%)Alcohol consumptionYes30 (48.7%)Weight (kg) maleMean ± SD32 (40%)Weight (kg) femaleMean ± SD31 (16.2%)BMI female218.540 (81.7%)BMI female218.540 (81.7%)SGA218.540 (81.7%)SGA218.540 (81.7%)SGA218.540 (81.7%)Total protein (g/L)Mean ± SD22 (43.8%)Type and protein (g/L)Mean ± SD22 (43.8%)Type and protein (g/L)Mean ± SD22 (43.8%)Total protein (g/L)Mean ± SD22 (40.1 </td <td></td> <td><math>\geq 63</math></td> <td>42 (52.5%)</td>		$\geq 63$	42 (52.5%)
Histopuloogical diagnosisSquamous cell carcinoma80 (100%)Innour locationLarynx36 (45%)T stage2 (28.8%)23 (28.8%)1 stage4 (56.3%)4N stage018 (22.5%)1 and the stage11 (13.8%)2 (28.8%)445 (56.3%)1 and the stage11 (13.8%)2 (28.8%)445 (56.3%)1 and the stage45 (55.3%)2 (28.8%)445 (56.3%)1 and the stage45 (55.3%)2 (28.8%)445 (56.3%)2 (28.8%)445 (56.3%)2 (28.8%)445 (56.3%)2 (28.8%)11 (13.8%)45 (56.3%)2 (28.8%)11 (13.8%)50 (62.5%)2 (28.8%)10 (23.7%)66.3%)1 (29.3%)10 (23.7%)66.3%)2 (29.3%)11 (16.3%)23 (45.7%)2 (29.4%)11 (16.3%)23 (45.7%)2 (10.5%)11 (16.3%)23 (45.7%)2 (10.5%)11 (16.4%)23 (45.7%)2 (10.5%)11 (16.4%)23 (43.7%)2 (10.5%)11 (16.4%)23 (43.7%)2 (10.5%)11 (16.4%)23 (43.7%)2 (10.5%)11 (16.4%)23 (43.7%)2 (10.5%)11 (16.4%)23 (43.7%)2 (10.5%)11 (16.4%)23 (43.7%)2 (10.5%)11 (16.4%)23 (43.7%)2 (10.5%)11 (16.4%)23 (43.7%)2 (10.5%)11 (16.4%)23 (43.7%)2 (10.5%)11 (16.4%)23 (43.7%)<		<63	38 (47.5%)
Tumou locationLarynx44 (5%)OrophaynxSo (4%)1 stage2 (14.9%)3 a2 (28.8%)A4 (55.3%)A4 (55.3%)1 stage1 (13.8%)1 a1 (13.8%)2 a4 (5%)1 a1 (13.8%)2 b1 (13.8%)2 b3 (3.7%)Disease stageII (1III a1 (13.8%)Disease stage10 (6.7%)VC0 (6.7%)Performance status (PS)0 (6.7%)Performance status (PS)0 (6.7%)Performance status (PS)10 (23.7%)Performance status (PS)0 (3.7%)Prope of treatment2 (40%)Alcohol consumptionYesYes30 (3.7%)Nonomoker30 (3.5%)Alcohol consumptionYesYeight (kg) maleSonokerWeight (kg) femaleMean + SDBMI female2 (16.4%)Weight (kg) femaleMean + SDBMI female2 (16.4%)Status2 (18.5BMI female2 (18.5)Alphany (kg) female2 (3.5%)Status2 (3.5%)Status2 (3.5%)Alphany (kg) female2 (3.5%)Alphany (kg) female2 (3.5%)Alphany (kg) female2 (3.5%)Alphany (kg) female3 (3.7%)Alphany (kg) female2 (3.5%)Alphany (kg) female3 (3.7%)Alphany (kg) female2 (3.5%)Alphany (kg) female2 (3.5%) <td>Histopathological diagnosis</td> <td>Squamous cell carcinoma</td> <td>80 (100%)</td>	Histopathological diagnosis	Squamous cell carcinoma	80 (100%)
N stageNormalSet (SPS)1 stage323 (28.%)N stage432 (28.%)N stage018 (22.%)1 and the stage18 (22.%)1 and the stage18 (22.%)1 and the stage18 (22.%)1 and the stage18 (22.%)1 and the stage19 (23.%)1 and the stage10 (23.%)1 and the stage20 (25.%)1 and the stage20 (25.%)1 and the stage20 (25.%)1 and the stage20 (25.%)2 and the stage20 (25.%)2 and the stage20 (25.%)2 and the stage21 (24.%)2 and the stage21 (	Tumour location	Larynx	44 (55%)
T stage22221212141313121416 <td></td> <td>Oropharynx</td> <td>36 (45%)</td>		Oropharynx	36 (45%)
3321 (28.%)N stage018 (22.5%)1 (13.8%)11 (13.8%)244 (55%)244 (55%)244 (55%)37 (8.7%)Disease stageIIIIII19 (23.8%)VA50 (62.5%)Performance status (PS)0Performance status (PS)0Prior surgical treatmentYesNo32 (40%)Type of treatment19 (23.7%)Optical treatmentYesNo32 (40%)Alcohol consumptionYesNon-mocker30 (43.7%)Smoking statusSmokerNon-mocker13 (16.2%)Weight (kg) fernaleMeam ± SDMather23.36 ± 4.34MatherSDMather23.36 ± 4.34Mather23.36 ± 4.34MatherSDMatherSDMatherSDMather23.36 ± 4.34Mather23.36 ± 4.34MatherSDMatherSDMatherSDMather23.36 ± 4.34Mather23.36 ± 4.34MatherSDMatherSDMatherSDMatherSDMatherSDMatherSDMatherSDMatherSDMatherSDMatherSDMatherSDMatherSDMatherSDMatherSD <td>T stage</td> <td>2</td> <td>12 (14.9%)</td>	T stage	2	12 (14.9%)
4444N stage018 (22.5%)111 (13.8%)1112.2%44 (55%)3344 (55%)Disease stage11119 (23.8%)Disease stage1109 (62.5%)TVB50 (62.5%)50 (62.5%)Performance status (PS)06 (7.7%)Performance status (PS)06 (7.6%)Prior surgical treatmentYes48 (60%)Type of treatmentYes48 (60%)Type of treatment70 (23.7%)9 (48.7%)Alcohol consumptionYes30 (37.5%)Alcohol consumptionYes9 (48.7%)Smoking statusSomoker30 (37.5%)Weight (kg) maleKema + SD9 (48.7%)Weight (kg) maleMeam + SD61 +11BMI male218.511 (16.4%)Weight (kg) maleMeam + SD61 +11BMI male218.510 (81.7%)SGAA20 (25%)Attrast21 (25%)10 (81.7%)MRS21 (85.3%)10 (81.7%)Attrast21 (85.3%)10 (81.7%)Attrast21 (85.3%)20 (25%)Attrast33 (37.5%)10 (37.5%)Attrast33 (37.5%)10 (37.5%)Attrast21 (35.5%)10 (37.5%)Attrast21 (35.5%)10 (37.5%)Attrast21 (35.5%)10 (37.5%)Attrast21 (35.5%)10 (37.5%)Attrast21 (35.5%)10 (37.5%)A		3	23 (28.8%)
N stage018 (22.%)111 (13.8%)11 (13.8%)237(8.7%)Disease stage11119 (23.8%)Disease stage11119 (23.8%)VA50 (62.5%)1VA50 (62.5%)VFA6061 (76.3%)119 (23.7%)19 (23.7%)Performance status (PS)061 (76.3%)119 (23.7%)19 (23.7%)Prior surgical treatment19 (23.7%)Type of treatment24 (40%)Concurrent CRTH39 (48.7%)Alcohol consumptionYesNo30 (37.5%)No50 (62.5%)Concurrent CRTH39 (48.7%)Alcohol consumptionYesVeight (kg) femaleSmokerMonser67 (83.8%)No-smoker13 (16.2%)Current smoker11 (16.4%)Weight (kg) femaleMean ± SDBM1 male21.36 ± 4.31Mean ± SD23.6 ± 4.32Algen = SD21.6 ± 4.22≥ 18.516 (80%)SGAAlem ± SD21.6 ± 4.22NRS221.6 ± 4.22Albornin (g/L)Mean ± SD33.8 ± 0.26Preadbunning(d/L)Mean ± SD33.8 ± 0.26 </td <td></td> <td>4</td> <td>45 (56.3%)</td>		4	45 (56.3%)
1111 (13.8%)237 (8.7%)37 (8.7%)7 (8.7%)Disease stageIII19 (23.8%)WA50 (62.5%)50 (65)VID6 (7.6%)6 (7.6%)Performance status (PS)06 (7.6%)Prior surgical treatmentYes48 (60%)No32 (40%)32 (40%)Type of treatment41 (51.3%)30 (37.5%)Alcohol consumptionYes30 (37.5%)Smoking statusSmoker67 (83.8%)Monsmoker13 (16.2%)20 (62.5%)Weight (kg) maleMean ± SD61 ± 11BMI male21.6540 (81.7%)BMI female21.6540 (81.7%)SGACarcent status61 ± 11BMI male21.8540 (81.7%)SGACarcent status23.65 ± 4.43SGACarcent status21.65 ± 4.22SGAA20.25%)AA20.25%)SGACarcent status35 (43.8%)SGAA20.25%)SGAA20.25%)A33.63.2620.25%)SGAA20.25%)A33.7%)33.63.26SGAA33.7%)Total protein (g/L)Mean ± SD33.84.26Prealbuning(d/L)Mean ± SD33.84.26Prealbuning(d/L)Mean ± SD23.64.31Total protein (g/L)Mean ± SD33.64.05Prealbuning(d/L)Mean ± SD33.64.05Prealbuning(d	N stage	0	18 (22.5%)
2244 (5%)Disease stage1II19 (23.8%)UA5 (6%)5 (6%)VA5 (6%)6 (7.7%)Performance status (PS)06 (7.63.%)Prior surgical treatment119 (23.7%)Prior surgical treatment7 (8.7%)1No32 (40%)32 (40%)Type of treatment30 (48.7%)30 (37.5%)Alcohol consumptionYes30 (37.5%)Alcohol consumptionYes30 (37.5%)Smoking statusSmoker67 (63.6%)Meight (kg) maleMoner50 (63.6%)Weight (kg) fenaleMean ± SD67 ± 12Weight (kg) fenaleMean ± SD67 ± 12BMI male< 18.5		1	11 (13.8%)
37 (8.7%)Disease stage1119 (23.8%)IVA50 (62.5%)IVB106 (7.7%)Performance status (PS)06 (7.6%)Performance status (PS)010 (23.7%)Prior surgical treatmentYes48 (60%)Type of treatmentYes32 (40%)Type of treatment41 (51.3%)20 (25.%)Alcohol consumption41 (51.3%)30 (37.5%)Smoking status50 (62.5%)30 (37.5%)Smoking status50 (62.5%)30 (37.5%)Smoking status50 (62.5%)30 (37.5%)Weight (kg) maleKeam - SD50 (62.5%)Weight (kg) femaleMeam + SD61 ± 11BMI male218.549 (81.7%)BMI femaleKeam + SD61 ± 11SGAKash SD21.61 ± 4.22SGAKash SD21.61 ± 4.22SGAC21.51 ± 4.32SGAAla20.25%)B33.61 × 8.5531.61 × 8.55SGA20.25%)33.61 × 8.56SGA20.25%)33.61 × 8.56SGA20.25%)33.61 × 8.56SGA20.25%)33.61 × 8.56SGAAla ± SD33.61 × 8.56SGAAla ± SD33.61 × 8.56SGAAla ± SD33.62		2	44 (55%)
Disease stageIII19 (23.8%)IVA50 (62.5%)IVB50 (66.%)VC6 (7.7%)Performance status (PS)0119 (23.7%)Prior surgical treatmentYesNo22 (40%)Type of treatment44 (51.3%)Concurrent CRTH39 (48.7%)Alcohol consumptionYesNo50 (62.5%)Smoking statusSmokerMooker50 (63.5%)Smoking statusSmokerMoner smoker13 (16.2%)Current smoker13 (16.2%)Current smoker56 (83.6%)Prior smoker11 (16.4%)Weight (kg) femaleMean ± SDBMI female21.85BMI female21.85SGAAlcohol consumptionSGAAlcoholAltonin (g/L)Mean ± SDAltonin (g/L)SGAAltonin (g/L)Mean ± SDSGA20 (25%)Total protein (g/L)Mean ± SDAlbumin (g/L)Mean ± SD<		3	7 (8.7%)
VA $50 (62.5\%)$ VB $5(6\%)$ VC $6(7.7\%)$ Performance status (PS)       0 $6(7.5\%)$ Prior surgical treatment       Yes $48 (60\%)$ Type of treatment       Yes $48 (60\%)$ Type of treatment       Yes $48 (60\%)$ Type of treatment       Concurrent CKTH $39 (48.7\%)$ Acholo consumption       Yes $30 (62.5\%)$ Smoking status       Smoker $50 (62.5\%)$ Smoking status       Smoker $50 (62.5\%)$ Vegight (kg) male       Mean + SD $50 (62.5\%)$ Weight (kg) male       Mean ± SD $67 \pm 12$ Weight (kg) male       Mean ± SD $67 \pm 12$ Weight (kg) female       Mean ± SD $61 \pm 11$ BMI male $218.5$ $40 (81.7\%)$ SGA       I (18.3\%) $218.5$ $42 (20\%)$ SGA       A $20 (25\%)$ R       C $23 (24.44)$ $33 (43.45)$ SGA       A $20 (25\%)$ $33 (43.45)$ SGA       A $20 (25\%)$ $33 (43.45)$	Disease stage	III	19 (23.8%)
NB PCS (6%) (7.%)Performance status (PS)06 (7.5%)Prior surgical treatment19 (23.7%)19 (23.7%)Prior surgical treatmentYes88 (60%)Type of reatmentRTH alone41 (51.3%)Alcohol consumptionYes30 (37.5%)Alcohol consumptionYes30 (37.5%)Snokirg statusSonoker67 (83.8%)Weight (kg) maleMoon-smoker13 (16.2%)Weight (kg) fenaleMean ± SD67 ±12Weight (kg) fenaleMean ± SD61 ±11BMI male23.65 ±4.4321.65 ±4.22Algament21.85 ±4.3311 (18.3%)SGAAls21.85 ±4.33SGAAls21.85 ±4.33AlgamentS (33.8%)23.65 ±4.43AlgamentS (33.8%)23.65 ±4.43AlgamentS (33.65 ±4.43)21.65 ±4.22Algament21.85 ±4.2321.65 ±4.22AlgamentS (33.6%)11 (18.3%)SGAAlgamentS (33.8%)23.65 ±4.43AlgamentBaS (33.8%)23.65 ±4.43SGAAlgamentS (33.8%)23.65 ±4.43SGAAlgamentS (33.8%)23.65 ±4.43SGAAlgamentS (33.8%)23.65 ±4.43SGAAlgamentS (33.8%)23.65 ±4.43SGAAlgamentS (33.8%)33.8 ±0.26NRSAlgamentS (33.8%)33.8 ±0.26NRSAlgamentS (33.8%)33.8 ±0.26Total protein (g/L)M	-	IVA	50 (62.5%)
Performance status (PS)IVC6 (7.7%)Performance status (PS)061 (76.3%)Prior surgical treatmentYes48 (60%)No32 (40%)32 (40%)Type of treatmentRTH alone41 (51.3%)Acohol consumptionYes30 (37.5%)Acohol consumptionYes30 (37.5%)Smoking statusSmoker67 (83.8%)Smoking statusSmoker67 (83.8%)Weight (kg) maleMeam 4SD67 (41.2%)Weight (kg) femaleMeam 4SD61 ± 11BMI male21.8511 (16.4%)Status21.8511 (18.3%)StatusSite Status61 ± 11BMI maleMeam 4SD23.36 ± 4.43BMI maleMeam 4SD23.36 ± 4.43StatusSite Status11 (18.3%)StatusSite Status11 (18.3%)StatusMeam 4SD21.06 ± 4.22Martin Status21.8511 (18.3%)StatusA20.25%)StatusSite Status3.38 ± 0.26NRSG3.38 ± 0.26NRSSite Status3.38 ± 0.26Prealbuning (JL)Meam 4SD0.24 ± 0.1Atloumin (gL)Meam 4SD0.24 ± 0.1Prealbuning (JL)Meam 4SD0.24 ± 0.1Prealbuning (JL) </td <td></td> <td>IVB</td> <td>5 (6%)</td>		IVB	5 (6%)
Performance status (PS)06 (76.3%)Prior surgical treatment119 (23.7%)Prior surgical treatmentNo32 (40%)Type of treatmentRTH alone41 (51.3%)Concurrent CRTH39 (48.7%)30 (37.5%)Alcohol consumptionYes30 (37.5%)Smoking statusSmoker30 (37.5%)Moreatment13 (16.2%)13 (16.2%)Current smoker67 (83.8%)13 (16.2%)Weight (kg) maleMean ± SD67 ± 12Weight (kg) femaleMean ± SD67 ± 12BMI female11 (16.4%)23.36 ± 4.43EMI female21.8.549 (81.7%)SGAAlconol22.16 ± 4.22SGAAlconol22.16 ± 4.22MRSAlso20.25%)RA20.25%)35 (43.8%)MRSAlconol25.01.2%)Total protein (g/L)Mean ± SD25.01.2%)Albumin (g/L)Mean ± SD25.01.2%)Total protein (g/L)Mean ± SD33.8 ± 0.26Preabunin(g/L)Mean ± SD3.38 ± 0.26Preabunin(g/L)Mean ± SD2.50 ± 0.53Transferin (g/L)Mean ± SD2.50 ± 0.53Therw (ng/L)Mean ± SD2.50 ± 0.53Transferin (g/L)Mean ± SD2.50 ± 0.53Transfe		IVC	6 (7.7%)
$\begin{array}{cccccc} 1 & 1 & 19 & (23.7\%) \\ \mbox{Pior surgical treatment} & Yes & 48 & (60\%) \\ \mbox{No} & 32 & (40\%) \\ \mbox{Type of treatment} & RTH alone & 41 & (51.3\%) \\ \mbox{Concurrent CRTH} & 39 & (48.7\%) \\ \mbox{Alcohol consumption} & Yes & 30 & (37.5\%) \\ \mbox{No} & No & 50 & (62.5\%) \\ \mbox{Sinoking status} & No & 50 & (62.5\%) \\ \mbox{Sinoking status} & No & 50 & (62.5\%) \\ \mbox{Sinoking status} & No & 50 & (62.5\%) \\ \mbox{Current smoker} & 67 & (83.8\%) \\ \mbox{Current smoker} & 13 & (16.2\%) \\ \mbox{Current smoker} & 16 & (83.6\%) \\ \mbox{Former smoker} & 11 & (16.4\%) \\ \mbox{Weight (kg) male} & Mean \pm SD & 61 \pm 11 \\ \mbox{BMI male} & Mean \pm SD & 61 \pm 11 \\ \mbox{BMI male} & Mean \pm SD & 23.36 \pm 4.43 \\ \mbox{21 ls.5} & 11 & (18.3\%) \\ \mbox{BMI female} & Mean \pm SD & 22.16 \pm 4.22 \\ \mbox{21 ls.5} & 11 & (18.3\%) \\ \mbox{SGA} & A & 20 & (25\%) \\ \mbox{BMI female} & 18.5 & 16 & (80\%) \\ \mbox{SGA} & A & 20 & (25\%) \\ \mbox{BMI female} & 218.5 & 42 & (20\%) \\ \mbox{SGA} & A & 20 & (25\%) \\ \mbox{BMI female} & 218.5 & 16 & (80\%) \\ \mbox{Current smoker} & 23 & (34.8\%) \\ \mbox{Current smoker} & 23 & (34.8\%) \\ \mbox{Current smoker} & 20 & (25\%) \\ \mbox{BMI female} & 20 & (25\%) \\ $	Performance status (PS)	0	61 (76.3%)
$\begin{array}{llllllllllllllllllllllllllllllllllll$		1	19 (23.7%)
$\begin{array}{cccc} No & & & & & & & & & & & & & & & & & & $	Prior surgical treatment	Yes	48 (60%)
$\begin{array}{ccc} \mbox{Type of treatment} & RTH alone & 41 ($1.3\%) \\ Concurrent CRTH & 39 (48.7\%) \\ Alcohol consumption & Yes & 30 (37.5\%) \\ No & 50 (62.5\%) \\ Smoking status & Smoker & 67 (83.8\%) \\ No on-smoker & 67 (83.8\%) \\ No-smoker & 13 (16.2\%) \\ Current smoker & 13 (16.2\%) \\ Current smoker & 11 (16.4\%) \\ Weight (kg) male & Mean \pm SD & 61 \pm 11 \\ BMI male & Mean \pm SD & 23.36 \pm 4.43 \\ \geq 18.5 & 49 (81.7\%) \\ c18.5 & 11 (18.3\%) \\ BMI female & Mean \pm SD & 22.16 \pm 4.22 \\ \geq 18.5 & 49 (81.7\%) \\ c18.5 & 11 (18.3\%) \\ BMI female & Mean \pm SD & 22.16 \pm 4.22 \\ \geq 18.5 & 16 (80\%) \\ c18.5 & 16 (80\%$		No	32 (40%)
$\begin{array}{ccc} \mbox{Concurrent CRTH} & 39 (48.7\%) \\ \mbox{Alcohol consumption} & Yes & 30 (37.5\%) \\ \mbox{No} & No & 50 (62.5\%) \\ \mbox{Smoking status} & Smoker & 13 (16.2\%) \\ \mbox{Current smoker} & 56 (83.6\%) \\ \mbox{Current smoker} & 56 (83.6\%) \\ \mbox{Current smoker} & 56 (83.6\%) \\ \mbox{Former smoker} & 11 (16.4\%) \\ \mbox{Weight (kg) male} & Mean \pm SD & 61 \pm 11 \\ \mbox{BMI male} & Mean \pm SD & 61 \pm 11 \\ \mbox{BMI male} & Mean \pm SD & 61 \pm 11 \\ \mbox{BMI male} & Mean \pm SD & 23.6 \pm 4.43 \\ \mbox{$\geq 18.5$} & 49 (81.7\%) \\ \mbox{$< 18.5$} & 11 (18.3\%) \\ \mbox{BMI female} & Mean \pm SD & 22.16 \pm 4.22 \\ \mbox{$\geq 18.5$} & 11 (18.3\%) \\ \mbox{BMI female} & Mean \pm SD & 22.16 \pm 4.22 \\ \mbox{$\geq 18.5$} & 16 (80\%) \\ \mbox{$< 18.5$} & 4 (20\%) \\ \mbox{$SGA$} & A & 20 (25\%) \\ \mbox{BMI SCA} & 25 (31.2\%) \\ \mbox{SGA} & A & 20 (25\%) \\ \mbox{BMI SCA} & 21 (3.2\%) \\ \mbox{CL} & 25 (31.2\%) \\ \mbox{AMI SD} & 23 (3.7\%) \\ \mbox{CL} & 25 (31.2\%) \\ \mbox{AMI SD} & 338 \pm 0.26 \\ \mbox{Prealburnin (g/L)} & Mean \pm SD & 338 \pm 0.26 \\ \mbox{Prealburnin (g/L)} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 3.38 \pm 0.26 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Cpurl} & Mean \pm SD & 2.50 \pm 0.53 \\ \mbox{Thr} \mbox{Thr} \mbox{Thr} \mbox{Thr} \mbox{Thr} \mbox{Thr} \ \mbox{Thr} \mbox{Thr} Thr$	Type of treatment	RTH alone	41 (51.3%)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Type of deductions	Concurrent CRTH	39 (48 7%)
$\begin{array}{cccc} Note Contain prior & No & So & So & So & So & So & So & So$	Alcohol consumption	Ves	30 (37 5%)
	r neonor consumption	No	50 (62 5%)
$\begin{array}{cccc} \text{Ninexel} & \text{Sintexel} & Sinte$	Smoking status	Smoker	67 (83.8%)
$\begin{tabular}{ c c c c } & Vorment smoker & 15 (10.2.%) \\ & Vorment smoker & 56 (83.6\%) \\ & Former smoker & 11 (16.4\%) \\ & Veight (kg) male & Mean \pm SD & 67 \pm 12 \\ & Weight (kg) female & Mean \pm SD & 61 \pm 11 \\ & BMI male & Mean \pm SD & 23.36 \pm 4.43 \\ & \geq 18.5 & 49 (81.7\%) \\ & <18.5 & 11 (18.3\%) \\ & BMI female & Mean \pm SD & 22.16 \pm 4.22 \\ & \geq 18.5 & 16 (80\%) \\ & <18.5 & 16 (80\%) \\ & <18.5 & 420\% \\ & SGA & A & 20 (25\%) \\ & B & 35 (43.8\%) \\ & C & 25 (31.2\%) \\ & NRS & 2 & C & 25 (31.2\%) \\ & VRS & VRS & VRS & VRS & VRS \\ & VRS & VRS & VRS & VRS & VRS \\ & VRS & VRS$	Shloking status	Non-smoker	13(162%)
$\begin{tabular}{ c c c c c } \hline Current shoker & 11 (16.4\%) \\ \hline Former smoker & 11 (16.4\%) \\ \hline Weight (kg) male & Mean \pm SD & 61 \pm 11 \\ \hline Weight (kg) female & Mean \pm SD & 23.36 \pm 4.43 \\ \geq 18.5 & 23.36 \pm 4.43 \\ \geq 18.5 & 49 (81.7\%) \\ <18.5 & 11 (18.3\%) \\ \hline C & 18.5 & 11 (18.3\%) \\ \hline SGA & A & 20 (25\%) \\ \hline B & 218.5 & 16 (80\%) \\ <18.5 & 4 (20\%) \\ \hline SGA & A & 20 (25\%) \\ \hline B & 35 (43.8\%) \\ \hline C & 25 (31.2\%) \\ \hline NRS & 2 & 57 (71.3\%) \\ \hline 3 & 20 (25\%) \\ \hline A & 3 (3.7\%) \\ \hline Total protein (g/L) & Mean \pm SD & 6.65 \pm 0.54 \\ \hline Housing (gL) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.24 \pm 0.1 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g/L) & Mean \pm SD & 0.25 \pm 0.53 \\ \hline Transferrin (g$		Current smoker	56 (83.6%)
		Former smoker	11(164%)
Weight (kg) femaleMean $\pm$ SD $0/112$ Weight (kg) femaleMean $\pm$ SD $61 \pm 11$ BMI male $\geq 18.5$ $49 (81.7\%)$ $\geq 18.5$ $49 (81.7\%)$ $\in 18.5$ $11 (18.3\%)$ BMI femaleMean $\pm$ SD $\geq 18.5$ $16 (80\%)$ $\leq 18.5$ $16 (80\%)$ $\leq 18.5$ $16 (20\%)$ SGAA $RS$ $20 (25\%)$ $RS$ $2$ $RS$ $2$ $10 \text{ protein (g/L)}$ Mean $\pm$ SD $Albumin (g/L)$ Mean $\pm$ SD $2.50 \pm 0.54$ $Albumin (g/L)$ Mean $\pm$ SD $2.50 \pm 0.53$ $Tora (protein (g/L)$ Mean $\pm$ SD $2.50 \pm 0.53$ $The \alpha (pg/mL)$ Mean $\pm$ SD $2.50 \pm 0.53$ $TNF - \alpha (pg/mL)$ Mean $\pm$ SD $9.92 \pm 1.56$	Weight (kg) male	Mean + SD	67 + 12
Weight (kg) EnlactMean $\pm$ SD01 $\pm$ 11BMI maleMean $\pm$ SD23.36 $\pm$ 4.43 $\geq$ 18.5 $\neq$ 9 (81.7%) $\leq$ 18.511 (18.3%)BMI femaleMean $\pm$ SD22.16 $\pm$ 4.22 $\geq$ 18.516 (80%) $<$ 18.516 (80%) $<$ 18.54 (20%)SGAA20 (25%)B35 (43.8%)C25 (31.2%)NRS257 (71.3%) $2$ 320 (25%)43 (3.7%)Total protein (g/L)Mean $\pm$ SD3.38 $\pm$ 0.26Prealbumin (g/L)Mean $\pm$ SD0.24 $\pm$ 0.1Transferrin (g/L)Mean $\pm$ SD2.50 $\pm$ 0.53TNF- $\alpha$ (pg/mL)Mean $\pm$ SD9.92 $\pm$ 1.56	Weight (kg) famale	Mean + SD	$67 \pm 12$ $61 \pm 11$
BMI finaleMean $\pm$ SD25,30 $\pm$ 4,43 $\geq 18.5$ 49 (81.7%)BMI femaleMean $\pm$ SD $\geq 18.5$ 16 (80%) $\geq 18.5$ 16 (80%) $< 18.5$ 4 (20%)SGAAD20 (25%)B35 (43.8%)C25 (31.2%)NRS223257 (71.3%)320 (25%)43 (3.7%)Total protein (g/L)Mean $\pm$ SDAlbumin (g/L)Mean $\pm$ SDPrealbumin(g/L)Mean $\pm$ SDNF- $\alpha$ (pg/mL)Mean $\pm$ SDNF- $\alpha$ (pg/mL)Mean $\pm$ SD9.92 $\pm$ 1.56	PMI malo	$M_{con} + SD$	$01 \pm 11$ 22 26 ± 4 42
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Bivii illaic	> 12.5	$25.50 \pm 4.43$
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		$\leq 10.5$	49 (01.770)
BMI femaleMean $\pm$ SD22.16 $\pm$ 4.22 $\geq 18.5$ 16 (80%) $< 18.5$ 4 (20%)SGAA20 (25%)B35 (43.8%)C25 (31.2%)NRS257 (71.3%)320 (25%)43 (3.7%)Total protein (g/L)Mean $\pm$ SDAlbumin (g/L)Mean $\pm$ SDPrealbumin(g/L)Mean $\pm$ SDPrealbumin(g/L)Mean $\pm$ SDTotal protein (g/L)Mean $\pm$ SDNF- $\alpha$ (pg/mL)Mean $\pm$ SDSGA2.50 $\pm$ 0.53TNF- $\alpha$ (pg/mL)Mean $\pm$ SD	DMI famala	< 16.J Maan + SD	11(10.5%)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Divit temate	19.5	$22.10 \pm 4.22$
$\begin{array}{cccc} < 18.5 & 4 & (20\%) \\ & & & & & & & & & & & & & & & \\ & & & & & & & & & & & & \\ & & & & & & & & & & & & \\ & & & & & & & & & & & \\ & & & & & & & & & & & \\ & & & & & & & & & & & \\ & & & & & & & & & & \\ & & & & & & & & & & \\ & & & & & & & & & & \\ & & & & & & & & & & \\ & & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & \\ & & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\$		≥18.5	16 (80%)
SGAA $20 (25\%)$ B $35 (43.8\%)$ C $25 (31.2\%)$ NRS22 $57 (71.3\%)$ 3 $20 (25\%)$ 4 $3 (3.7\%)$ Total protein (g/L)Mean ± SDAlbumin (g/L)Mean ± SDPrealbumin(g/L)Mean ± SDPrealbumin(g/L)Mean ± SDTransferrin (g/L)Mean ± SDTransferrin (g/L)Mean ± SDTNF- $\alpha$ (pg/mL)Mean ± SDSD $9.92 \pm 1.56$	004	< 18.5	4 (20%)
$\begin{array}{cccc} B & 35 (43.8\%) \\ C & 25 (31.2\%) \\ 125 (31.2\%) \\ 2 & 57 (71.3\%) \\ 3 & 20 (25\%) \\ 4 & 3 (3.7\%) \\ 105 (25\%) \\ 4 & 3 (3.7\%) \\ 105 (25\%) \\ 105 (2$	SGA	A	20 (25%)
NRSC25 (31.2%)NRS257 (71.3%)320 (25%)43 (3.7%)Total protein (g/L)Mean $\pm$ SD6.65 $\pm$ 0.54Albumin (g/L)Mean $\pm$ SD3.38 $\pm$ 0.26Prealbumin(g/dL)Mean $\pm$ SD0.24 $\pm$ 0.1Transferrin (g/L)Mean $\pm$ SD2.50 $\pm$ 0.53TNF- $\alpha$ (pg/mL)Mean $\pm$ SD9.92 $\pm$ 1.56		B	35 (43.8%)
NRS2 $5/(7/1.3\%)$ 33 $20 (25\%)$ 43 (3.7\%)Total protein (g/L)Mean ± SD $6.65 \pm 0.54$ Albumin (g/L)Mean ± SD $3.38 \pm 0.26$ Prealbumin(g/dL)Mean ± SD $0.24 \pm 0.1$ Transferrin (g/L)Mean ± SD $2.50 \pm 0.53$ TNF- $\alpha$ (pg/mL)Mean ± SD $9.92 \pm 1.56$		C	25 (31.2%)
$3$ $20 (25\%)$ $4$ $3 (3.7\%)$ Total protein (g/L)Mean ± SDAlbumin (g/L)Mean ± SDPrealbumin (g/L)Mean ± SD $2.50 \pm 0.54$ Transferrin (g/L)Mean ± SDTransferrin (g/L)Mean ± SDTNF- $\alpha$ (pg/mL)Mean ± SD $9.92 \pm 1.56$	NRS	2	57 (71.3%)
4 $3(3.7\%)$ Total protein (g/L)       Mean ± SD $6.65 \pm 0.54$ Albumin (g/L)       Mean ± SD $3.38 \pm 0.26$ Prealbumin(g/dL)       Mean ± SD $0.24 \pm 0.1$ Transferrin (g/L)       Mean ± SD $2.50 \pm 0.53$ TNF- $\alpha$ (pg/mL)       Mean ± SD $9.92 \pm 1.56$		3	20 (25%)
Total protein (g/L)       Mean $\pm$ SD $6.65 \pm 0.54$ Albumin (g/L)       Mean $\pm$ SD $3.38 \pm 0.26$ Prealbumin(g/L)       Mean $\pm$ SD $0.24 \pm 0.1$ Transferrin (g/L)       Mean $\pm$ SD $2.50 \pm 0.53$ TNF- $\alpha$ (pg/mL)       Mean $\pm$ SD $9.92 \pm 1.56$		4	3 (3.7%)
Albumin (g/L)         Mean $\pm$ SD $3.38 \pm 0.26$ Prealbumin(g/L)         Mean $\pm$ SD $0.24 \pm 0.1$ Transferrin (g/L)         Mean $\pm$ SD $2.50 \pm 0.53$ TNF- $\alpha$ (pg/mL)         Mean $\pm$ SD $9.92 \pm 1.56$	Total protein (g/L)	Mean $\pm$ SD	$6.65 \pm 0.54$
Prealbumin(g/dL)         Mean $\pm$ SD $0.24 \pm 0.1$ Transferrin (g/L)         Mean $\pm$ SD $2.50 \pm 0.53$ TNF- $\alpha$ (pg/mL)         Mean $\pm$ SD $9.92 \pm 1.56$	Albumin (g/L)	Mean $\pm$ SD	$3.38 \pm 0.26$
Transferrin (g/L)         Mean $\pm$ SD         2.50 $\pm$ 0.53           TNF- $\alpha$ (pg/mL)         Mean $\pm$ SD         9.92 $\pm$ 1.56	Prealbumin(g/dL)	Mean $\pm$ SD	$0.24 \pm 0.1$
TNF- $\alpha$ (pg/mL) Mean ± SD 9.92 ± 1.56	Transferrin (g/L)	Mean $\pm$ SD	$2.50 \pm 0.53$
	TNF- $\alpha$ (pg/mL)	Mean $\pm$ SD	$9.92 \pm 1.56$

## **Nutritional assessment**

The values of anthropometric parameters such as body weight and body mass index (BMI) as well as parameters obtained from electrical bioimpedance analysis (BIA) reflecting body composition, i.e. fat mass (FM) and fat free mass (FFM), were evaluated at two time points, before and after RTH. In addition, subjective nutritional status was assessed using Subjective Global Assessment (SGA), while Nutrition Risk Score (NRS-2002) was used to assess the risk of malnutrition development in HNC patients. Next, the values of the examined parameters were compared in order to evaluate their changes after the treatment completion, quantitative and percentage weight loss, BMI and FM were assessed.

BIA was performed using ImpediMed SFB7 BioImp v1.55 bioimpedance analysis device (Pinkenba, QLD, Australia). The same examination conditions were provided for each patient. BIA was performed in the morning, in fasting condition and in supine position with straightened limbs apart from each other and not in contact with the rest of the body. The electrodes were placed on the right side of the patient's body. Prior to BIA, patients laid down for several minutes to stabilize and balance their body fluids. The measurements were repeated three times, and the results were averaged. FM and fat-free mass (FFM) values obtained by means of BIA were used in the study.

## **PLIN1genotyping**

DNA was isolated from whole blood samples collected on EDTA using DNA Blood Mini Kit (Qiagen, Canada). Genotyping was performed using real-time PCR, commercially available fluorescent TaqMan SNP genotyping assay (ThermoFisherScientific, USA) targeting the studied SNP and allele discriminating software. DNA amplification was performed using Genotyping Master Mix (ThermoFisherScientific, USA) kit in StepOnePlus Real-Time PCR System (Applied Biosystems, USA). All steps in the determination of the SNP, from isolation to data analysis, were performed according to the protocols provided by the reagent manufacturer.

#### **Statistical analysis**

The MedCalc software version 15.8 (MedCalc software, Belgium) was applied to statistical analysis and graph generation. Data distribution was tested by Shapiro-Wilk method. Based on the test result, all of the studied parameters demonstrated normal distribution of the data; hence, we used parametrical tests in our calculations. Differences in the value of studied parameters among patients with different genotype distribution were tested by one-way analysis of variance (ANOVA test) as well as the Student's t test compared data difference between the two groups. Frequency of the PLIN1 genotype depending on the clinical-demographic features of the patients was tested by chisquare and Fisher's exact test. Impact of the studied clinicaldemographic and nutritional parameters on the chance of the FM reduction during the RTH was analysed by univariate and multivariate logistic regression model with the odds ratio calculation and corresponding 95% confidence interval (OR and 95% CI). The results presenting p values below 0.05 were considered as statistically significant.

# Results

The following genotype distribution of the studied *PLIN1* gene polymorphism was obtained in the study group: AA in 29 patients (36.2%), GA in 37 patients (46.3%) and GG in 14 cases (17.5%). The distribution of genotypes was consistent with the Hardy-Weinberg's equilibrium (HWE) in the entire

study group (p = 0.712) as well as among men (p = 0.757) and women (p = 0.858). The distribution of SNP genotypes did not depend on the clinical-demographic features of HNC patients, such as age, gender, disease stage and anatomical location of the tumour or the treatment applied before RTH. There were no significant differences in the studied parameters between patients previously treated surgically (p > 0.05) (Supplementary Table 1).

The differences in the anthropometric parameter values (body weight, BMI) and body composition parameters (FM and FFM) in relation to the genotype before and after RTH are presented in Table 2. Significant differences in BMI and FM were observed in the group of men before and after RTH. AA genotype carriers had significantly lower BMI than GA and GG genotypes (mean BMI:  $22.61 \pm 4.64$  and  $22.75 \pm 4.09$  and  $27.12 \pm 2.45$ , respectively; p = 0.034). Men with AA genotype also had significantly lower FM compared with the carriers of other genotypes (mean FM:  $18.73 \pm 7.69$  kg for AA and  $19.60 \pm 7.08$  kg and  $26.84 \pm 4.50$  kg for GA and GG, respectively; p = 0.037). A similar relationship was observed in A allele carriers compared with GG genotype. At the end of 7 RTH cycles, significant changes in both anthropometric and body composition parameters were observed. Similarly to the measurements performed before the initiation of treatment, significant differences were observed only in men. After the completion of RTH, HNC patients with A haplotype had significantly lower body weight, BMI value and FM compared with men with GG genotype: mean body weight:  $59.15 \pm$ 8.98 kg and  $68.43 \pm 8.02$  kg (p = 0.014), mean BMI: 20.71  $\pm 3.29$  and  $25.19 \pm 1.88$  (*p* = 0.011) as well as mean FM:  $15.50 \pm 5.49$  kg and  $26.76 \pm 5.18$  kg (p < 0.001). Comparing only homozygous patients, men with AA genotype had significantly lower body weight (p = 0.020; Fig. 1a) and BMI (p = 0.012; Fig. 1b) in contrast to GG genotype carriers. Moreover, AA genotype carriers had significantly lower FM values compared with G allele carriers (GG and GA): FM FM  $13.84 \pm 6.36$  kg and  $19.06 \pm 6.30$  kg (p = 0.009) (Fig. 1c).

Since significant changes in the studied parameter values were observed only in the group of men diagnosed with HNC, further analysis was performed in this group of patients. In result of the treatment, 34 men (56.7% of the male subjects) had malnutrition defined as  $\geq 5\%$  body weight loss before RTH. The highest percentage of malnourished men was found in the group of AA genotype carriers (76.2%), which was significantly higher than in the case of patients with GA and GG genotypes (53.6% and 27.3%) (p = 0.027). With regard to FM in consequence of RTH, the AA genotype carriers lost an average of 37.01% fat mass and patients with GA and GG genotypes lost 12.82 and 0.31% (p = 0.035)(Fig. 2a), respectively. After the completion of treatment in the group of patients with GG genotype, the mean FM loss was < 0.1 kg (p =0.725, Fig. 2b), in men with GA genotype the mean loss was 2.89 kg (p = 0.141, Fig. 2c) and in carriers of AA genotype

Table 2 The differences in the anthropometric parameter values (body weight, BMI) and body composition parameters (FM and FFM) in relation to the genotype before and after RTH

Factor	GG	GA	AA	р	AA	GA+GG	р	GG	GA+AA	р
Measurements	prior to RTH									
Weight (kg)	$70.19 \pm 11.21$	$65.92 \pm 11.12$	$64.00\pm12.83$	0.376	$64.00\pm12.83$	$67.19 \pm 11.17$	0.326	$70.19 \pm 11.21$	$65.06 \pm 11.82$	0.198
group Weight (kg)	$72.11\pm11.65$	$65.60 \pm 11.29$	$66.47 \pm 12.13$	0.616	$66.47 \pm 12.13$	$67.50\pm11.37$	0.722	$72.11 \pm 11.65$	$65.98 \pm 11.51$	0.102
Weight (kg) women	$64.0 \pm 11.79$	$66.75\pm9.98$	$53.20\pm9.96$	0.173	$53.20\pm9.96$	$65.86 \pm 11.0$	0.111	$64.0\pm11.79$	$59.86 \pm 13.17$	0.617
BMI group	$25.47 \pm 3.89$	$22.96 \pm 4.43$	$22.74 \pm 4.84$	0.227	$22.74 \pm 4.84$	$23.71\pm4.39$	0.443	$25.47 \pm 3.89$	$22.86 \pm 4.57$	0.095
BMI men	$27.12\pm2.45$	$22.75\pm4.09$	$22.61 \pm 4.64$	0.034	$22.61 \pm 4.64$	$23.77 \pm 4.18$	0.904	$27.12\pm2.45$	$23.11\pm4.29$	0.021
BMI women	$22.61\pm4.60$	$24.55\pm6.22$	$19.88 \pm 4.22$	0.405	$19.88 \pm 4.22$	$23.44 \pm 5.57$	0.214	$22.61 \pm 4.60$	$21.43\pm6.14$	0.748
FM (kg)	$23.75\pm11.11$	$19.52\pm6.76$	$17.01\pm7.84$	0.144	$17.01\pm7.84$	$21.07 \pm 8.48$	0.077	$23.75\pm11.11$	$18.40\pm7.29$	0.053
group FM (kg)	$26.84 \pm 4.50$	$19.60\pm7.08$	$18.73\pm7.69$	0.037	$18.73\pm7.69$	$21.29 \pm 7.21$	0.258	$26.84 \pm 4.50$	$19.23\pm7.26$	0.011
FM (kg) women	$21.08\pm14.50$	$18.88\pm4.37$	$9.72\pm2.50$	0.394	$9.72\pm2.50$	$20.14\pm13.39$	0.166	$21.08\pm14.50$	$13.65\pm5.79$	0.337
FM (%) group	$32.28\pm9.26$	$29.05\pm7.01$	$25.75 \pm 8.64$	0.093	$25.75\pm8.64$	$30.0\pm7.76$	0.060	$32.28\pm9.26$	$27.58\pm7.87$	0.090
FM (%) men	$36.30\pm4.02$	$29.28\pm7.41$	$27.45\pm8.65$	0.067	$27.45\pm8.65$	$30.92\pm7.36$	0.155	$36.30\pm4.02$	$28.51 \pm 7.92$	0.015
FM (%)	$25.24\pm12.25$	$27.32\pm2.16$	$18.47\pm3.26$	0.330	$18.47\pm3.26$	$26.13\pm8.82$	0.135	$25.24\pm12.25$	$22.26\pm5.41$	0.582
FFM (kg)	$49.28\pm8.26$	$47.31\pm7.04$	$47.92\pm7.09$	0.756	$47.92\pm7.09$	$47.90\pm7.36$	0.990	$49.28\pm8.26$	$47.59\pm7.00$	0.487
FFM (kg) men	$47.13\pm5.74$	$46.98 \pm 7.11$	$47.99 \pm 7.70$	0.902	$47.99\pm7.70$	$47.01\pm 6.72$	0.650	$47.13\pm5.74$	$47.41\pm7.29$	0.922
FFM (kg) women	$53.06 \pm 11.48$	$49.87\pm7.32$	$47.62\pm4.38$	0.668	$47.62\pm4.38$	$51.69 \pm 9.31$	0.439	$53.06 \pm 11.48$	$48.58\pm5.38$	0.393
Measurements	after commence	ment of RTH								
Weight (kg) group	$65.10\pm10.23$	$60.04 \pm 8.84$	$56.47 \pm 9.31$	0.081	$56.47 \pm 9.31$	$61.54\pm9.42$	0.053	$65.10\pm10.23$	$58.45\pm9.13$	0.038
Weight (kg) men	$68.43\pm8.02$	$59.91 \pm 8.87$	$58.12\pm9.30$	0.042	$58.12\pm9.30$	$61.90\pm9.29$	0.187	$68.43\pm8.02$	$59.15\pm8.98$	0.014
Weight (kg) women	$59.25\pm12.15$	$60.50\pm8.66$	$49.80\pm5.25$	0.182	$49.80\pm5.25$	$60.0\pm10.57$	0.105	$59.25\pm12.15$	$54.43\pm9.62$	0.484
BMI group	$23.64 \pm 3.64$	$20.97 \pm 3.76$	$20.00 \pm 3.18$	0.064	$20.00 \pm 3.18$	$21.76 \pm 4.05$	0.093	$23.64 \pm 3.64$	$20.54 \pm 3.65$	0.014
BMI men	$25.19 \pm 1.88$	$20.82\pm3.52$	$20.56 \pm 3.06$	0.005	$20.56\pm3.06$	$21.84 \pm 3.70$	0.233	$25.19 \pm 1.88$	$20.71\pm3.29$	0.011
BMI women	$20.93 \pm 4.67$	$22.41 \pm 6.47$	$18.65 \pm 3.33$	0.524	$18.65\pm3.33$	$21.44 \pm 5.67$	0.249	$20.93 \pm 4.67$	$19.56\pm5.52$	0.687
FM (kg)	$23.45\pm10.89$	$16.79 \pm 4.74$	$13.42\pm5.77$	< 0.001	$13.42\pm5.77$	$19.07\pm7.82$	0.006	$23.45\pm10.89$	$15.28\pm5.43$	< 0.001
FM (kg) men	$26.76\pm5.18$	$16.71\pm4.51$	$13.84\pm6.36$	< 0.001	$13.84\pm6.36$	$19.06\pm6.30$	0.009	$26.76\pm5.18$	$15.50\pm5.49$	< 0.001
FM (kg) women	$20.40\pm11.52$	$17.33\pm7.47$	$11.60 \pm 1.00$	0.258	$11.60\pm1.00$	$19.08 \pm 13.20$	0.300	$20.40\pm11.52$	$14.05\pm5.33$	0.382
FM (%) group	$32.53\pm9.09$	$27.19\pm5.22$	$22.96 \pm 6.44$	0.001	$22.96 \pm 6.44$	$28.77\pm6.93$	0.003	$32.53\pm9.09$	$25.30\pm6.12$	0.002
FM (%) men	$36.51\pm4.40$	$27.11 \pm 5.17$	$23.44 \pm 6.99$	< 0.001	$23.44 \pm 6.99$	$29.30\pm6.38$	0.005	$36.51 \pm 4.40$	$25.55\pm6.21$	< 0.001
FM (%) women	$25.57 \pm 11.63$	$27.78\pm6.78$	$20.91\pm3.03$	0.537	$20.91\pm3.03$	$26.52\pm9.18$	0.275	$25.57 \pm 11.63$	$23.86\pm5.78$	0.748
FFM (kg) group	$47.76\pm7.18$	$44.23\pm6.72$	$43.99 \pm 7.08$	0.302	$43.99 \pm 7.08$	$45.28\pm6.95$	0.506	$47.76\pm7.18$	$44.13\pm6.81$	0.121
FFM (kg) men	$46.32\pm4.75$	$44.32\pm7.03$	$43.90\pm7.37$	0.731	$43.90\pm7.37$	$44.78\pm6.55$	0.672	$46.32\pm4.75$	$44.14\pm7.08$	0.440
FFM (kg) women	$50.27\pm10.65$	$43.57\pm4.48$	$44.43\pm6.68$	0.494	$44.43\pm6.68$	$47.40\pm8.73$	0.574	$50.27\pm10.65$	$44.07\pm5.41$	0.233

5.88 kg (p = 0.005, Fig. 2d). Moreover, it was found that the percentage of men who lost at least 10%, 20% or 30% body

weight in result of treatment was the highest in the group of patients with AA genotype. Significant FM loss defined as fat



**Fig. 1** Differences in the anthropometrical parameters and fat mass (FM) between group of male patients carrying various *PLIN1* genotypes—measurements after the RTH: **a** comparison of the body weight between

loss of  $\ge 20\%$  or  $\ge 30\%$  was observed in 52.4% and 38.1% of patients with AA genotype, respectively. These percentages were significantly higher than in carriers of other genotypes (p = 0.004 and p = 0.037). We did not observed any significant differences concerning FFM values. The differences in the values of the studied anthropometric and FM parameters (before and after RTH) according to *PLIN1* genotype are presented in Table 3.

In the last stage of the study, we assessed the factors that significantly affect the chances of FM loss (in three models, respectively:  $\geq 10\%$ ,  $\geq 20\%$  and  $\geq 30\%$ ) following RTH in the study group of men with HNC. All patient clinical and demographic features, anthropometric parameters, BIA and the treatment applied were included in the analyses. Univariate analysis selected only AA genotype as a predictive factor significantly affecting the risk of FM loss in each of the studied models. Patients with AA genotype were 8, 5 and 2 times more likely to lose  $\geq 10\%$ ,  $\geq 20\%$  and  $\geq 30\%$  FM than the carriers of other genotypes, respectively. In the multivariate analysis, which included all the clinical-demographic-

AA and GG homozygous patients; **b** differences in BMI between AA and GG homozygous patients, and **c** comparison of FM values among all PLIN1 genotype carriers

nutritional data of the studied men, a significant influence of AA genotype on the chance of FM loss during RTH was also observed. Unfavourable predictive factors of  $\geq$  10% loss were SGA-C (OR = 3.78, *p* = 0.043) and AA genotype (OR = 13.78, *p* = 0.032), of  $\geq$  20% loss, it was AA genotype (OR = 5.78, *p* = 0.010) and of  $\geq$  30% loss, it was also AA genotype (OR = 2.28, *p* = 0.023) (Table 4).

# Discussion

The incidence of malnutrition observed in HNC patients in radiological wards can reach even 80%. The presence of malnutrition is associated with unfavourable prognosis of the disease, higher mortality and deterioration of the quality of life; therefore, it is necessary to identify the patients with high risk of malnutrition and cachexia [18]. Based on the above, the classical definition of malnutrition has been extended and also refers to other factors conducive to the development of malnutrition, apart from those related to tumour presence and



Fig. 2 Changes in fat mass (FM) as a consequence of the RTH: a percentage change in FM depending on *PLIN1* genotypes; changes in FM as a consequence of the RTH expressed in kg: b changes in the group GG carriers; c changes in the group GA carriers; d changes in the group AA carriers

systemic metabolic disorders. It is believed that any involuntary weight  $loss \ge 5\%$  within 1 month is a reliable indicator of malnutrition associated with hospitalization and treatment [19]. This emphasizes that the therapy and the adverse events associated with it may significantly affect the dynamics of malnutrition development, even in such short periods of time, which are close to the duration of radical RTH (6-8 weeks). Currently used subjective methods of nutrition evaluation such as SGA or NRS and anthropometric parameters such as body weight and BMI may be insufficient to detect malnutrition and malnutrition associated with significant FM loss. Despite the loss of fat mass, the above parameters may be correct, thus masking the development of malnutrition. Therefore, it seems justified to search for molecular predictive markers of malnutrition that reflect the status of the organism at the cellular level.

Some studies show that white adipose tissue is one of the first organs affected by malnutrition or cachexia, the symptom of which is the reduction of its mass, often without visible muscle tissue loss. Increased mobilization of fat tissue in both syndromes is associated with increased activity of ATGL and HSL lipases, whose access to triglycerides stored in fat drops is regulated by perilipin [20]. It has also been noted that the impairment of perilipin function stimulates the development of inflammatory response in adipocytes by secretion of proinflammatory fat metabolites resulting from their uncontrolled breakdown [21]. To date, several SNPs have been identified in the perilipin-coding gene, including rs 1052700, rs 894160, rs 2289487 and rs 2304795 (13041A>G), which are associated with the risk of obesity associated with fat accumulation, increased BMI and body weight [17]. SNP 13041 A > G seems to have a significant influence on perilipin activity due to its

**Table 3** Changes in theanthropometrical and nutritionalparameters in a consequence ofthe RTH in different genotypecarriers of *PLIN1* 

Factor— mean changes after RTH	GG	GA	AA	р
Weight	-4.82%	-5.0%	-7.20%	0.284
Weight loss > 5%	3/11 (27.3%)	15/28 (53.6%)	16/21 (76.2%)	0.027
BMI	-7.08%	- 7.96%	-10.80%	0.387
FM	-0.31%	-12.82%	-37.01%	0.035
FM loss (kg)	-0.10	-2.89	- 5.88	0.011
FM loss > 10%	3/11 (27.3%)	15/28 (53.6%)	16/21 (76.2%)	0.027
FM loss > 20%	0/11 (0%)	6/28 (21.4%)	11/21 (52.4%)	0.004
FM loss > 30%	0/11 (0%)	5/28 (17.9%)	8/21 (38.1%)	0.037
FFM loss (kg)	-0.81	-2.66	-4.09	0.642
Factor—mean changes after RTH	GG and GA		AA	р
Weight	-4.92%		-7.20%	0.173
Weight loss > 5%	18/39 (46.2%)		16/21 (76.2%)	0.031
BMI	-7.77%		-10.80%	0.217
FM	-7.73%		-37.01%	0.012
FM loss (kg)	-2.23		- 5.88	0.033
FM loss > 10%	18/39 (46.2%)		16/21 (76.2%)	0.031
FM loss > 20%	6/39 (15.4%)		11/21 (52.4%)	0.006
FM loss > 30%	5/39 (12.8%)		8/21 (38.1%)	0.045
FFM loss (kg)	-2.23		-4.09	0.438

genomic location. It is located in the 3' region of the gene—a place of alternative splicing, where various isoforms of perilipin are formed during PLIN1 transcription, manifesting varied protective activity of fats against their lipolysis [22]. In a study of 734 subjects, Qi et al. noted a higher incidence of the G allele of 13041A>G and its influence on the risk of the development of obesity. The authors confirmed the relationship between SNP and obesity only in the group of women. The average percentage of fat tissue in women was 30.6%, 32.7% and 33.3% in AA, GA and GG genotypes respectively (p = 0.016). Moreover, G allele carriers (GG and GA) had significantly higher BMI and obesity risk (OR = 1.73) than women with AA genotype [23].

In another study conducted by the same authors, in a group of over 4000 subjects of Asian origin, it was observed that the presence of the GG 13041A>G genotype was associated with the risk of obesity approximately twice as high as in patients with GA and AA variants. This trend was observed in the Malaysian population; whereas in the obese individuals of Chinese and Indian origin, the G allele frequency was higher [24]. In another study, Jenkis et al. made similar observations in a group of the obese elderly subjects. Individuals carrying AA genotype had significantly lower BMI and fat content than those carrying other genotypes. Even after 6 months of workout to reduce body weight and body fat, AA genotype carriers reported significantly lower BMI and body fat mass than other individuals [25]. Our findings seem to be consistent with those obtained in those studies, although we only reported statistically significant results for men. Men with A haplotype had significantly lower BMI and FM before the start of treatment compared with GA or GG genotype carriers (p =0.021 and 0.011, respectively). After the RTH the AA men

Table 4	Factors affecting the
chance of	of fat mass loss during the
course o	of RTH

Factor	Univariate	analysis	Multivariate analysis		
	р	OR [95%CI]	р	OR [95%CI]	
loss of FM > 10%					
AA genotype	0.043	8.12 [0.892-43.844]	0.032	13.78 [1.247–152.31]	
SGA-C	-	-	0.043	3.78 [0.803–17.844]	
loss of FM $> 20\%$					
AA genotype	0.013	5.04 [1.399-18.175]	0.010	5.78 [1.521-21.932]	
loss of FM $> 30\%$					
AA genotype	0.018	2.23 [0.687-7.247]	0.028	2.28 [0.892–15.435]	
-				-	

had significantly lower FM compared with G haplotype carriers (p = 0.009). Interestingly, we observed that in result of the treatment, men with AA genotype lost a much higher percentage of body fat than the carriers of GA and GG genotypes, with the loss of -0.31%, -12.82% and -37.01% (*p* = 0.035), respectively. The percentage of malnourished patients was also higher in the group of men with AA genotype (76.2%) than in patients with GA and GG genotypes (46.2%) (p = 0.031). The presence of AA genotype had a significant influence on the chance of FM loss during RTH; > 10% FM (OR = 13.78), >20% FM (OR = 5.78) and >30% FM (OR = 2.28). Few studies did not confirm the relationship between 13041A>G and the body nutritional parameters. Soenenen et al. and Ruiz et al. evaluated the influence of low calorie and low energy diets on body composition parameters in relation to PLIN1 13041A>G genotype. They did not report any significant correlations between the genotype variants of the studied SNPs and the body composition parameters in subjects after a 12-week diet [26, 27]. It should be noted, however, that these studies were aimed at the evaluation of the influence of diet on weight reduction in relation to the genotype. To this day, there have been no studies on the influence of PLIN1 polymorphisms on the nutritional status of malignant tumours and their relation to the treatment used. Perhaps the mechanism associated with the regulation of perilipin activity is completely different in cancer patients because other pathways of lipolysis are additionally activated. Radical RTH may also have a significant influence on the regulation of inflammatory and metabolic response of the organism, hence the genotypic variants of perilipin conditioned by 13041A>G may manifest different protective activity of adipose tissue against uncontrolled lipolysis. The evaluation of such molecular factors as SNP 13041A>G may also have higher predictive value in the development of malnutrition associated with severe loss of fat mass than the subjective scales, e.g. SGA and NRS-2002. NRS scoring did not significantly affect the chance of FM loss during RTH, while the presence of SGA-C was associated only with the chance of FM loss above 10% (OR = 3.78 compared with OR = 13.78 for AA genotype).

Our study is not devoid of some limitations. First of all, it was performed in a relatively small group of patients. In our group, there is also a disproportion in the number of men and women (3:1) as a result of more frequent occurrence of HNC in men. In the quoted studies, the ratio was 1:1 or 1:2, which may have resulted in a lack of correlation between the assessed SNP and the body composition parameters in the studied women. Moreover, we performed the evaluation at two time points, before and after the treatment completion. The evaluation carried out after each RTH cycle could more clearly show the dynamics of changes in body composition. Despite these limitations, it should be noted that this is the first study to evaluate the *PLIN1* 13041A>G value in predicting

adverse changes in body composition during RTH. The presence of AA genotype on men with HNC before RTH may facilitate earlier nutritional intervention and supportive treatment aimed at limiting or preventing body mass and fat mass loss during the applied treatment. According to literature data, most HNC patients require nutritional intervention at regular intervals during RTH [28]. The results of our study should be confirmed in larger groups of patients, especially including higher number of women, in order to finally confirm the predictive value of SNP in patients with HNC treated with radical RTH.

#### **Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Informed consent** All persons gave their informed consent prior to their inclusion in the study.

**Involving human participants** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

### References

- Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, Compher C, Correia I, Higashiguchi T, Holst M, Jensen GL, Malone A, Muscaritoli M, Nyulasi I, Pirlich M, Rothenberg E, Schindler K, Schneider SM, de van der Schueren MAE, Sieber C, Valentini L, Yu JC, van Gossum A, Singer P (2017) ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 36:49–64
- Gorenc M, Kozjek NR, Strojan P (2015) Malnutrition and cachexia in patients with head and neck cancer treated with (chemo)radiotherapy. Rep Pract Oncol Radiother 20(4):249–258
- Langius JA, Doornaert P, Spreeuwenberg MD et al (2010) Radiotherapy on the neck nodes predicts severe weight loss in patients with early stage laryngeal cancer. Radiother Oncol 97(1): 80–85
- Unsal D, Mentes B, Akmansu M, Uner A, Oguz M, Pak Y (2006) Evaluation of nutritional status in cancer patients receiving radiotherapy: a prospective study. Am J Clin Oncol 29(2):183–188

- Munshi A, Pandey MB, Durga T, Pandey KC, Bahadur S, Mohanti BK (2003) Weight loss during radiotherapy for head and neck malignancies: what factors impact it? Nutr Cancer 47(2):136–140
- Tolentino ES, Centurion BS, Ferreira LHC et al (2011) Oral adverse effects of head and neck radiotherapy: literature review and suggestion of a clinical oral care guideline for irradiated patients. J Appl Oral Sci 19(5):448–454
- Haghjoo S (2015) Malnutrition associated with head and neck cancers. Rev Clin Med 2(2):76–79
- Jackson W, Alexander N, Schipper M, Fig L, Feng F, Jolly S (2014) Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual-energy x-ray absorptiometry. Head Neck 36(9):1356– 1362
- 9. Alamada-Correira I, Neves PM, Makitie A, Ravasco P (2019) Body composition evaluation in head and neck cancer patients: a review. Front Oncol 9:1112
- Trayhurn P, Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60(3):329–339
- 11. Dalal S (2019) Lipid metabolism in cancer cachexia. Ann Palliat Med 8(1):13–23
- Wensveen FM, Valentić S, Šestan M, Turk Wensveen T, Polić B (2015) Interactions between adipose tissue and the immune system in health and malnutrition. Semin Immunol 27(5):322–333
- Morales PE, Bucarey JL, Espinosa A (2017) Muscle lipid metabolism: role of lipid droplets and Perilipins. J Diabetes Res 1789395: 1–10
- Blanchette-Mackie EJ, Dwyer NK, Barber T, Coxey RA, Takeda T, Rondinone CM, Theodorakis JL, Greenberg AS, Londos C (1995) Perilipin is located on the surface layer of intracellular lipid droplets in adipocytes. J Lipid Res 36(6):1211–1226
- Miyoshi H, Souza SC, Zhang HH, Strissel KJ, Christoffolete MA, Kovsan J, Rudich A, Kraemer FB, Bianco AC, Obin MS, Greenberg AS (2006) Perilipin promotes hormone-sensitive lipase-mediated adipocyte lipolysis via phosphorylation-dependent and -independent mechanisms. J Biol Chem 281(23):15837–15844
- Yu D, Li C, Xie J, Xu G, Li Y, Liu J, Chen B, Pan J, Shen M, Yang L, Hu D (2013) Association between three genetic variants of the perilipin gene (PLIN) and glucose metabolism: results from a replication study among Chinese adults and a meta-analysis. Endocr Res 38(4):263–279
- 17. Smith CE, Ordovás JM (2012) Update on perilipin polymorphisms and obesity. Nutr Rev 70(10):611–621
- Koom WS, Ahn SD, Song SY, Lee CG, Moon SH, Chie EK, Jang HS, Oh YT, Lee HS, Keum KC (2012) Nutritional status of patients

treated with radiotherapy as determined by subjective global assessment. Radiat Oncol J 30(3):132–139

- Kang WX, Li W, Huang SG, Dang Y, Gao H (2016) Effects of nutritional intervention in head and neck cancer patients undergoing radiotherapy: a prospective randomized clinical trial. Mol Clin Oncol 5(3):279–282
- Tsoli M, Schweiger M, Vanniasinghe AS, Painter A, Zechner R, Clarke S, Robertson G (2014) Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. PLoS One 9(3):e92966
- Sohn JH, Lee YK, Han JS, Jeon YG, Kim JI, Choe SS, Kim SJ, Yoo HJ, Kim JB (2018) Perilipin 1 (Plin1) deficiency promotes inflammatory responses in lean adipose tissue through lipid dysregulation. J Biol Chem 293(36):13974–13988
- Lu X, Gruia-Gray J, Copeland NG, Gilbert DJ, Jenkins NA, Londos C, Kimmel AR (2001) The murine perilipin gene: the lipid dropletassociated perilipins derive from tissue-specific, mRNA splice variants and define a gene family of ancient origin. Mamm Genome 12(9):741–749
- Qi L, Shen H, Larson I, Schaefer EJ, Greenberg AS, Tregouet DA, Corella D, Ordovas JM (2004) Gender-specific association of a perilipin gene haplotype with obesity risk in a white population. Obes Res 12(11):1758–1765
- Qi L, Tai ES, Tan CE, Shen H, Chew SK, Greenberg AS, Corella D, Ordovas JM (2005) Intragenic linkage disequilibrium structure of the human perilipin gene (PLIN) and haplotype association with increased obesity risk in a multiethnic Asian population. J Mol Med (Berl) 83(6):448–456
- 25. Jenkins NT, McKenzie JA, Damcott CM et al (2010) Endurance exercise training effects on body fatness, VO2max, HDL-C subfractions, and glucose tolerance are influenced by a PLIN haplotype in older Caucasians. J Appl Physiol 108(3):498–506
- Soenen S, Mariman EC, Vogels N et al (2009) Relationship between perilipin gene polymorphisms and body weight and body composition during weight loss and weight maintenance. Physiol Behav 96(4–5):723–728
- Ruiz JR, Larrarte E, Margareto J, Ares R, Alkorta P, Labayen I (2011) Preliminary findings on the role of PLIN1 polymorphisms on body composition and energy metabolism response to energy restriction in obese women. Br J Nutr 106(4):486–490
- Cady J (2007) Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement. Clin J Oncol Nurs 11(6):875–880

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.